drugset / Trial / NCT06995326
A Study of SGB-3383 in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3383 in healthy subjects. The study will be designed as a single ascending dose (SAD) phase, utilizing a double-blind, placebo-controlled approach.
Timeline
- Start
- 2025-06
- Primary completion
- 2026-08
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGB-3383 | Unknown | — | Subcutaneous |
Indications
No indication recorded.